Facet Hypertrophy | Diagnosis & Disease Information
WEBSep 12, 2022 · Facet hypertrophy is a common condition that occurs when the facet joints in the spine become enlarged. The facet joints are synovial joints in the spine where two vertebrae come into contact. They help to stabilize the spine during bending and twisting motions. Facet hypertrophy can be unilateral or bilateral and can happen for a variety of ...
2022 ACR/AAHKS Guidelines for Management of
WEBApr 6, 2022 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty: guideline summary.
Hydroxyapatite Crystal Deposition Disease (HADD)
WEBNov 15, 2022 · Hydroxyapatite deposition disease (HADD) is a condition where hydroxyapatite crystals accumulate in the soft tissues surrounding joints, leading to inflammation, tenderness, and pain. It primarily affects women around the age of 45 and commonly affects the glenohumeral joint in the shoulder. Other joints such as the hip, knee, elbow, wrist, and ...
Ehlers-Danlos Syndrome - Rheumatology Advisor
WEBEhlers-Danlos syndrome is a group of inherited connective tissue disorders that primarily affects the skin, joints, and blood vessel walls 1 but can affect every organ system and result in significant morbidity and mortality. 2 Typical clinical manifestations are skin hyperelasticity, hypermobility of joints, the fragility of blood vessels, 2 ...
Calcium Pyrophosphate Deposition Disease (CPPD)
WEBOct 5, 2022 · Calcium pyrophosphate deposition disease (CPPD) is a crystal deposition arthropathy that involves the synovial and periarticular tissues, 1 often characterized by painful swelling in one or more joints. 2 Other names that have been traditionally used for CPPD are chondrocalcinosis, pyrophosphate arthropathy, and most especially, pseudogout. 3 ...
Leukocytoclastic Vasculitis - Rheumatology Advisor
WEBAug 4, 2022 · Biopsy-proven leukocytoclastic vasculitis occurs with an estimated incidence of 4.5 per 100,000 person-years in the United States. 1 Research estimates the prevalence in different locations to range from 2.7 to 29.7 per million. 1. The incidence of leukocytoclastic vasculitis seems to be evenly distributed across different ages …
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
WEBAug 9, 2022 · Undifferentiated connective tissue disease (UCTD) is a diagnosis of exclusion. Patients who present with clinical and serolotical manifestations that suggest a systemic autoimmune disease but do not fulfill criteria for defined connective tissue disease (eg, systemic lupus erythematosus, scleroderma, myositis, rheumatoid arthritis, Sjogren's syndrome) are classified to have UCTD.
Viscosupplementation for Knee Osteoarthritis - Rheumatology …
WEBMar 25, 2019 · Viscosupplementation is a medical procedure during which a gel-like fluid called hyaluronic acid is injected into the knee joint. Hyaluronic acid is a naturally occurring lubricant that allows for smoother joint movement. It is found in lower concentrations in patients with knee osteoarthritis.
Drug-Induced Lupus | Diagnosis & Disease Information
WEBAug 4, 2022 · At least 46 drugs that are currently in use may cause drug-induced lupus. 4 The drugs most commonly associated with drug-induced lupus are hydralazine, procainamide, isoniazid, and quinidine. 2. The risk for developing lupus-like disease from any other drugs is low or very low. 2. There is a drug-induced lupus mnemonic to …
American College of Rheumatology Releases Updated Guidelines …
WEBJun 18, 2021 · The American College of Rheumatology (ACR) recently released updated guidelines for the pharmacologic management of rheumatoid arthritis (RA). The full report has been published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.. Overall, the updated guidelines include treatment with disease-modifying antirheumatic drugs (DMARDs), including biologic DMARDs (bDMARDs) and ...